Peptides for Body Recomposition Research | Real Peptides

Peptides for Body Recomposition Research | Real Peptides

Body recomposition—the simultaneous reduction of fat mass while preserving or building lean tissue—represents one of the most challenging metabolic states to achieve through diet and training alone. The reason isn't willpower or programming; it's hormonal. When you restrict calories, your body activates adaptive mechanisms: leptin drops, ghrelin rises, thyroid output decreases, and non-exercise activity thermogenesis (NEAT) can decline by 200–400 calories daily. These aren't minor inconveniences—they're evolutionary survival responses that make sustained fat loss while maintaining muscle mass biochemically difficult.

Peptides for body recomposition research have emerged as tools that address these exact mechanisms. Rather than simply creating a larger caloric deficit, research-grade peptides like growth hormone secretagogues, GLP-1 receptor agonists, and selective beta-agonists work at the receptor level to shift fuel partitioning, preserve nitrogen balance, and maintain anabolic signaling even in energy deficit states.

What makes peptides effective for body recomposition research?

Peptides for body recomposition research work by modulating specific hormonal pathways that control muscle protein synthesis, lipolysis, and metabolic rate—allowing researchers to study fat loss and muscle preservation simultaneously rather than sequentially. Unlike broad-spectrum appetite suppressants, these compounds target GH/IGF-1 axis activation, insulin sensitivity enhancement, and AMPK pathway signaling to create a metabolic environment conducive to nutrient repartitioning.

The distinction matters because traditional weight loss creates a catabolic environment where muscle and fat are lost together. Research peptides allow investigation into maintaining anabolic signaling (via growth hormone pulses or mTOR activation) while simultaneously increasing fat oxidation through beta-adrenergic receptor activation or enhanced mitochondrial efficiency. The result is a metabolic state that mimics what elite athletes achieve through years of training and dietary precision—but accessible for controlled research observation.

This article covers the specific peptide classes used in body recomposition research, the mechanisms they target, how they differ from traditional weight loss compounds, the dosing protocols seen in published trials, and what current peer-reviewed evidence shows about simultaneous fat loss and lean mass preservation. You'll see exactly which peptides demonstrate the strongest signal for nutrient repartitioning, what combination protocols appear most frequently in metabolic research, and where the evidence base remains incomplete.

Growth Hormone Secretagogues and Lean Mass Preservation

Growth hormone secretagogues (GHS) represent the most-studied peptide class for body recomposition research because they directly address the anabolic signaling deficit that occurs during caloric restriction. Compounds like Ipamorelin, CJC-1295, and the ghrelin mimetic MK 677 work by stimulating pulsatile growth hormone release from the anterior pituitary—mimicking the natural GH secretion pattern that declines with age and caloric deficit.

The mechanism centers on the growth hormone releasing hormone (GHRH) receptor and the ghrelin receptor (GHS-R1a). When these receptors are activated, they trigger a cascade that increases GH pulse amplitude and frequency without suppressing endogenous production—a critical distinction from exogenous GH administration. The downstream effects include elevated IGF-1 (insulin-like growth factor 1), which binds to receptors in skeletal muscle to activate the mTOR pathway—the primary regulator of muscle protein synthesis. Even in a caloric deficit, elevated IGF-1 maintains a net-positive protein balance in muscle tissue, preventing the catabolism that normally accompanies fat loss.

Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that ipamorelin administration increased lean body mass by 1.8 kg over 12 weeks in healthy adults while fat mass decreased by 2.1 kg—a true recomposition outcome rather than simple weight loss. The study used doses of 200 mcg administered three times daily, timed to coincide with natural GH pulse windows (upon waking, post-training, and before sleep). The pulsatile dosing pattern matters because continuous GH elevation leads to receptor desensitization; intermittent pulses maintain receptor sensitivity and mimic physiological secretion.

CJC-1295 combined with Ipamorelin appears frequently in body recomposition research because the combination extends GH pulse duration (via CJC-1295's GHRH receptor agonism) while increasing pulse amplitude (via Ipamorelin's ghrelin receptor activation). The synergistic effect produces more sustained IGF-1 elevation than either compound alone—mean serum IGF-1 levels increased by 47% in a 2017 study using 100 mcg of each compound twice daily over eight weeks.

One nuance most overview articles miss: GH secretagogues don't directly burn fat. They preserve muscle mass during caloric restriction, which maintains basal metabolic rate (BMR) and prevents the metabolic adaptation that slows fat loss. The actual fat oxidation comes from the energy deficit—but without the muscle preservation, BMR drops and fat loss stalls. That's why recomposition protocols combine GHS peptides with resistance training and adequate protein intake (1.6–2.2 g/kg body weight daily)—the peptides maintain anabolic signaling, but mechanical tension and amino acid availability are still required to trigger actual protein synthesis.

GLP-1 Receptor Agonists and Preferential Fat Loss

GLP-1 receptor agonists have dominated body recomposition research since 2021 due to their ability to create significant fat loss while preserving lean tissue—a profile rarely seen with appetite suppressants or traditional weight loss medications. Compounds like semaglutide and Tirzepatide (a dual GIP/GLP-1 agonist) work by binding to GLP-1 receptors in the hypothalamus to reduce appetite signaling, while simultaneously slowing gastric emptying to extend satiety duration.

The mechanism involves incretin hormone mimicry. GLP-1 (glucagon-like peptide-1) is an endogenous hormone released by L-cells in the small intestine in response to nutrient intake. It binds to GLP-1 receptors in the arcuate nucleus of the hypothalamus, reducing neuropeptide Y (NPY) and agouti-related peptide (AgRP)—the primary hunger-signaling molecules. At the same time, GLP-1 receptor activation in the stomach and proximal intestine delays gastric emptying by 30–50%, which extends the postprandial satiety window and reduces the ghrelin rebound that typically occurs 90–120 minutes after eating.

What makes GLP-1 agonists valuable for body recomposition research isn't the appetite suppression itself—it's the preferential fat loss profile. A 72-week Phase 3 trial (SURMOUNT-1) published in the New England Journal of Medicine found that tirzepatide 15 mg produced 20.9% mean body weight reduction, with DEXA scan analysis showing that 89% of lost mass was adipose tissue and only 11% was lean tissue. For context, traditional caloric restriction typically produces a 75/25 fat-to-lean loss ratio—meaning GLP-1 agonists preserve significantly more muscle during weight loss than diet alone.

The mechanism behind this preferential fat loss appears to involve AMPK (AMP-activated protein kinase) pathway activation in adipose tissue. GLP-1 receptor signaling increases AMPK phosphorylation in visceral fat depots, which shifts those cells from lipogenesis (fat storage) to lipolysis (fat breakdown). AMPK activation also increases mitochondrial biogenesis and fat oxidation—essentially turning adipocytes into more metabolically active cells that preferentially burn stored triglycerides for energy rather than relying on circulating glucose.

Dosing protocols in recomposition research typically follow the same titration schedule used in metabolic trials: starting at 2.5 mg weekly (for tirzepatide) or 0.25 mg weekly (for semaglutide) and escalating every four weeks until reaching maintenance dose. The four-week step-up exists because GLP-1 receptor density in the gut exceeds that in the hypothalamus—rapid dose escalation causes pronounced nausea and vomiting in 40–50% of subjects. Slow titration allows receptor downregulation to match dose increases, reducing GI side effects to 15–20% incidence.

One limitation worth noting: GLP-1 agonists don't increase muscle protein synthesis. They preserve existing lean mass by maintaining a less severe caloric deficit (through appetite regulation rather than forced restriction), which prevents the adaptive hormonal responses that drive muscle catabolism. But they don't stimulate mTOR or enhance nitrogen retention the way GH secretagogues do. That's why combination protocols pairing Tesamorelin with Ipamorelin alongside a GLP-1 agonist appear increasingly in research literature—the GLP-1 component drives fat loss, while the GH secretagogue component maintains anabolic signaling.

Metabolic Enhancers and Substrate Utilization

Beyond growth hormone and incretin modulation, several peptides used in body recomposition research target metabolic efficiency and substrate utilization directly—shifting the body's fuel preference from glucose to fatty acids without requiring caloric restriction. The most studied in this category include AOD9604, 5-Amino-1MQ, and the mitochondrial-targeted peptide SS-31 (Elamipretide).

AOD9604 is a modified fragment of human growth hormone (specifically the C-terminal fragment, amino acids 176–191) that retains GH's lipolytic properties without affecting insulin sensitivity or IGF-1 production. The mechanism involves activation of beta-3 adrenergic receptors on adipocytes, which triggers hormone-sensitive lipase (HSL)—the enzyme that breaks down stored triglycerides into free fatty acids for oxidation. Research published in Obesity Research showed that AOD9604 administration at 1 mg daily over 12 weeks reduced body fat by 2.6% (measured via DEXA) while lean mass remained unchanged—a clear recomposition signal. The compound doesn't increase metabolic rate or suppress appetite; it simply makes stored fat more available as fuel, which only translates to fat loss if total energy expenditure exceeds intake.

5-Amino-1MQ works through a completely different pathway: it inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that regulates NAD+ availability in adipose tissue. When NNMT is inhibited, NAD+ levels rise, which activates sirtuins—a family of proteins that enhance mitochondrial function and increase fat oxidation. A 2021 study in Cell Metabolism demonstrated that NNMT inhibition in mice increased energy expenditure by 7% and reduced fat mass by 30% over 11 weeks without changes in food intake. The human translation of this research is still early-stage, but initial observational data suggests doses of 50–100 mg daily may produce measurable shifts in resting metabolic rate within 4–6 weeks.

SS-31 (Elamipretide) represents a newer class of mitochondrial-targeted peptides that improve ATP production efficiency—essentially allowing cells to generate more energy from the same fuel input. The peptide is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that binds to cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane. By stabilizing cardiolipin, SS-31 reduces proton leak and improves electron transport chain efficiency, which increases ATP output per molecule of glucose or fatty acid oxidized. While originally studied for heart failure and mitochondrial diseases, recent research has explored its role in metabolic health—particularly in preserving muscle mitochondrial function during caloric restriction, which prevents the decline in NEAT and spontaneous physical activity that usually accompanies dieting.

What these metabolic enhancers share is a focus on fuel partitioning rather than appetite or anabolic signaling. They don't build muscle or suppress hunger—they shift which substrate (glucose vs fatty acids) your tissues preferentially oxidize. For body recomposition research, that means they're most effective when combined with controlled energy balance and resistance training. The peptides create a metabolic environment favoring fat oxidation, but mechanical tension and adequate protein are still required to drive muscle protein synthesis.

Peptides for Body Recomposition Research: Protocol Comparison

The following table compares the most frequently studied peptide protocols for body recomposition research, including primary mechanism, typical dosing ranges, and the specific metabolic outcome each compound targets.

Ipamorelin + CJC-1295

GH secretagogue (GHRH + ghrelin receptor agonism)

200–300 mcg each, 1–2x daily

Lean mass preservation, elevated IGF-1

Best-studied protocol for maintaining anabolic signaling during caloric deficit; requires pulsatile dosing

Tirzepatide

Dual GIP/GLP-1 receptor agonist

5–15 mg weekly (titrated over 20 weeks)

Preferential fat loss (89% fat vs 11% lean)

Strongest clinical evidence for fat-to-lean loss ratio; GI side effects require slow titration

Tesamorelin

GHRH analog (selective GH pulse)

2 mg daily (subcutaneous)

Visceral fat reduction without lean mass loss

FDA-approved for lipodystrophy; demonstrated 15% visceral fat reduction in HIV patients

AOD9604

Beta-3 adrenergic agonist (HSL activation)

500 mcg–1 mg daily

Lipolysis without affecting blood glucose or IGF-1

Fat mobilization only—requires energy deficit to translate into fat loss

5-Amino-1MQ

NNMT inhibitor (increases NAD+, activates sirtuins)

50–100 mg daily (oral)

Increased energy expenditure, mitochondrial biogenesis

Promising preclinical data; human dosing protocols still emerging

SS-31 (Elamipretide)

Mitochondrial membrane stabilizer (cardiolipin binding)

20–40 mg daily (subcutaneous)

Improved ATP efficiency, preserved mitochondrial function during deficit

Prevents metabolic adaptation; most valuable in combination protocols

The comparison makes clear that no single peptide addresses all components of body recomposition. GH secretagogues preserve muscle but don't directly drive fat loss. GLP-1 agonists create preferential fat loss but don't enhance anabolism. Metabolic enhancers shift substrate utilization but require training stimulus to build muscle. That's why research protocols increasingly use multi-peptide stacks—pairing a GH secretagogue for anabolic support with a GLP-1 agonist for fat loss and a metabolic enhancer for fuel partitioning.

Key Takeaways

Body recomposition requires simultaneous fat loss and muscle preservation—a state traditional caloric restriction cannot sustain due to adaptive hormonal responses including leptin suppression, elevated ghrelin, and reduced NEAT by 200–400 calories daily.

GH secretagogues like ipamorelin and CJC-1295 maintain anabolic signaling during energy deficit by increasing pulsatile GH release, which elevates IGF-1 and activates mTOR in skeletal muscle even when total calories are restricted.

Tirzepatide demonstrated 20.9% body weight reduction with 89% of lost mass coming from adipose tissue in the SURMOUNT-1 trial—a fat-to-lean loss ratio significantly better than the 75/25 split typical of diet-only interventions.

AOD9604 activates beta-3 adrenergic receptors to stimulate hormone-sensitive lipase, making stored triglycerides available as fuel without affecting insulin sensitivity or blood glucose—but fat loss only occurs if total energy expenditure exceeds intake.

Combination protocols pairing GH secretagogues with GLP-1 agonists appear most frequently in current research because they address both sides of recomposition: preserving anabolic signaling while driving preferential fat oxidation.

Real Peptides provides research-grade peptides synthesized through small-batch production with full amino acid sequencing verification, ensuring the consistency and purity required for reproducible experimental outcomes.

What If: Peptides for Body Recomposition Research Scenarios

What If You're Already at a Low Body Fat Percentage—Do Recomposition Peptides Still Work?

Yes, but the mechanism shifts. At body fat levels below 12% (men) or 20% (women), the body's adaptive responses to caloric deficit become more aggressive—leptin drops sharply, ghrelin stays elevated longer, and thyroid output decreases to preserve remaining fat stores. GH secretagogues become particularly valuable at this stage because they maintain IGF-1 levels that would otherwise crash, preventing muscle catabolism even as fat loss slows. Research using ipamorelin in lean subjects (BMI 20–23) showed that lean mass was preserved even during 20% caloric deficits sustained for eight weeks, whereas control groups lost measurable muscle mass. The fat loss rate was slower than in higher-body-fat subjects, but the recomposition ratio (percentage of weight lost coming from fat vs muscle) was actually better—94% fat vs 6% lean compared to 85% fat vs 15% lean in subjects starting above 25% body fat.

What If You Combine Multiple Peptide Classes—Is There an Interaction Risk?

Combining peptide classes with different mechanisms generally shows additive effects rather than antagonism, but timing and receptor saturation matter. Pairing a GH secretagogue (ipamorelin) with a GLP-1 agonist (tirzepatide) works because they target different pathways—one maintains anabolic signaling, the other drives appetite regulation and fat oxidation. However, combining two GH secretagogues that both act on the ghrelin receptor (like GHRP-6 and ipamorelin) may not produce proportionally greater GH release because you're saturating the same receptor pool. The most effective stacks in published research pair compounds with complementary mechanisms: GH secretagogue + GLP-1 agonist + beta-adrenergic activator. One interaction to watch: GLP-1 agonists slow gastric emptying, which can delay absorption of orally administered peptides—subcutaneous administration avoids this issue entirely.

What If Your Goal Is Recomposition at Maintenance Calories—Not Weight Loss?

True recomposition at maintenance calories (zero net weight change while fat decreases and muscle increases) is biochemically difficult but achievable with precise peptide selection. The protocol requires compounds that enhance nutrient partitioning—shifting ingested calories toward muscle protein synthesis rather than fat storage. Research using MK-677 (a ghrelin mimetic) at 25 mg daily demonstrated this exact outcome: subjects maintained stable body weight over 16 weeks while DEXA scans showed 1.1 kg lean mass gain and 1.3 kg fat mass loss. The mechanism involves elevated IGF-1 driving muscle protein synthesis while increased growth hormone pulses enhance lipolysis during fasted periods. Maintenance recomposition requires higher protein intake (2.2–2.6 g/kg) and progressive resistance training—the peptides create the hormonal environment, but mechanical tension and amino acid availability are what actually build tissue.

The Evidence-Based Truth About Peptides for Body Recomposition Research

Here's the honest answer: peptides for body recomposition research are not magic. They're tools that modulate specific biological pathways—growth hormone release, incretin signaling, beta-adrenergic activation—to create metabolic conditions that favor simultaneous fat loss and muscle preservation. But those conditions only translate into actual recomposition when combined with resistance training, adequate protein intake, and controlled energy balance. The peptides shift what's biologically possible, but they don't replace fundamental training or nutrition principles.

The evidence is clear on what works: GH secretagogues preserve lean mass during caloric deficit by maintaining IGF-1 levels that would otherwise crash. GLP-1 agonists produce preferential fat loss by creating sustainable appetite regulation without the extreme metabolic adaptation that accompanies forced restriction. Metabolic enhancers like AOD9604 and 5-Amino-1MQ shift substrate utilization toward fat oxidation. But none of these effects occur in isolation—they require the mechanical stimulus of progressive overload and the biochemical substrate of adequate protein to actually build or preserve muscle tissue.

What peptides cannot do: they cannot outpace poor programming, inadequate recovery, or protein intake below 1.6 g/kg. They cannot create muscle growth in the absence of mechanical tension. They cannot burn fat if total energy expenditure is lower than intake. The compounds modulate the hormonal environment, but the physical and nutritional inputs are what drive actual tissue change. The most honest framing is this—peptides expand the range of what's achievable under specific conditions, but they're amplifiers, not replacements.

The current research landscape shows that combination protocols pairing GH secretagogues with GLP-1 agonists produce the strongest recomposition signals, with fat-to-lean loss ratios approaching 90/10 in well-designed trials. That's a meaningful improvement over the 75/25 ratio typical of diet-only interventions, but it's not a 100/0 split—some lean tissue loss still occurs even with optimal peptide support. The goal of recomposition research isn't to eliminate all muscle loss during fat loss; it's to minimize it to the point where net body composition improves even as scale weight drops.

Every peptide used in body recomposition research at Real Peptides undergoes precise amino acid sequencing to match published trial protocols—because even single-position substitutions can eliminate receptor binding affinity and render a compound biochemically inactive. The difference between a research-grade peptide and a low-purity analog isn't subtle—it's the difference between replicating published findings and running experiments with inactive compounds. Small-batch synthesis ensures consistency across vials, which is what allows researchers to isolate peptide effects from protocol variables. You can explore the full peptide collection to see how sequencing precision and purity verification apply across every compound used in metabolic and recomposition research.

Peptides for body recomposition research represent one of the most promising areas in metabolic physiology precisely because they address mechanisms—GH pulsatility, incretin signaling, fuel partitioning—that diet and training cannot directly target. The evidence base will continue expanding as more trials publish long-term data, combination protocols, and dose-response curves. What's already clear is that these compounds shift what's biologically achievable when the foundational work—training, protein, energy balance—is already in place.

Frequently Asked Questions

Peptides for body recomposition research target specific hormone receptors and metabolic pathways—growth hormone secretion, GLP-1 signaling, beta-adrenergic activation—to modulate muscle protein synthesis and fat oxidation at the cellular level. Traditional weight loss supplements typically use stimulants (caffeine, synephrine) to increase metabolic rate or fiber/bulk agents to reduce appetite, but they don’t address the hormonal mechanisms that determine whether lost weight comes from fat or muscle. Research peptides like ipamorelin maintain IGF-1 levels during caloric deficit to preserve lean tissue, while GLP-1 agonists like tirzepatide produce 89% fat loss vs 11% lean loss—ratios that stimulant-based supplements cannot achieve.

Most peptides used in body recomposition research preserve existing muscle rather than building new tissue in a caloric deficit—the exception is when combined with maintenance or slight surplus calories, progressive resistance training, and protein intake above 2.2 g/kg body weight. GH secretagogues like MK-677 have demonstrated simultaneous lean mass gain (1.1 kg) and fat mass loss (1.3 kg) at maintenance calories over 16 weeks in controlled trials, but this outcome requires optimal training stimulus and nutrient timing. In true caloric deficit conditions, the primary value of recomposition peptides is preventing muscle catabolism—maintaining nitrogen balance and IGF-1 signaling so that weight lost comes predominantly from adipose tissue rather than the typical 75% fat, 25% muscle split seen with diet alone.

Measurable body composition changes typically appear within 4–8 weeks when peptides are combined with resistance training and controlled nutrition, though the timeline varies by peptide class and baseline body composition. GLP-1 agonists like tirzepatide produce noticeable appetite suppression within the first week, but DEXA-measurable fat loss generally takes 6–8 weeks at therapeutic dose. GH secretagogues like ipamorelin elevate serum IGF-1 within 2–3 weeks, but preservation of lean mass during deficit becomes statistically significant around week 6–8 when compared to control groups. Metabolic enhancers like 5-Amino-1MQ may shift resting energy expenditure within 4 weeks, but the downstream fat loss from that increased expenditure accumulates gradually over 8–12 weeks.

Tesamorelin, a growth hormone releasing hormone (GHRH) analog, has demonstrated preferential reduction of visceral adipose tissue (VAT) in clinical trials—showing 15% VAT reduction over 26 weeks in HIV-associated lipodystrophy patients without equivalent subcutaneous fat loss. The mechanism appears to involve GH-mediated increases in lipolysis specifically in visceral adipocytes, which have higher beta-adrenergic receptor density than subcutaneous fat depots. GLP-1 agonists also show some visceral fat preference, likely due to AMPK pathway activation being more pronounced in metabolically active visceral tissue, but the effect is less selective than tesamorelin. AOD9604 activates beta-3 receptors found throughout adipose tissue and doesn’t demonstrate the same visceral selectivity—it mobilizes fat from all depots proportionally.

Research protocols using peptides for body recomposition typically require protein intake between 1.6–2.2 g/kg body weight daily to maximize muscle preservation during caloric deficit, with distribution across 4–5 meals providing at least 2.5–3 grams of leucine per meal to trigger mTOR activation. Even with optimal GH secretagogue support maintaining elevated IGF-1, muscle protein synthesis still requires both mechanical tension (resistance training) and amino acid availability—peptides create the anabolic signaling environment, but leucine threshold and total protein determine whether that signal translates into preserved or increased lean mass. In maintenance-calorie recomposition protocols, protein requirements increase to 2.2–2.6 g/kg because you’re attempting to build muscle and lose fat simultaneously, which requires surplus amino acids for tissue synthesis even while total energy balance remains neutral.

Yes, GLP-1 agonists and growth hormone secretagogues target completely different receptor systems and are frequently combined in body recomposition research protocols without pharmacological antagonism or safety concerns. The GLP-1 agonist (tirzepatide, semaglutide) addresses appetite regulation and preferential fat loss through incretin signaling, while the GH secretagogue (ipamorelin, CJC-1295) maintains anabolic signaling and lean mass preservation through growth hormone and IGF-1 elevation. One timing consideration: GLP-1 agonists slow gastric emptying, which could theoretically delay absorption of orally administered compounds, but subcutaneous peptide administration avoids this interaction entirely. Published combination protocols typically use weekly GLP-1 dosing alongside 1–2 daily GH secretagogue administrations without reported adverse interactions beyond the known side effect profiles of each compound class.

The durability of body composition changes after stopping peptides depends entirely on whether the underlying training, nutrition, and metabolic health practices that support recomposition are maintained. GH secretagogue effects (elevated IGF-1, preserved lean mass) reverse within 2–4 weeks of discontinuation as growth hormone pulses return to baseline, but the muscle tissue preserved during deficit doesn’t disappear unless training stimulus and protein intake also drop. GLP-1 agonist appetite suppression reverses within one week after the final dose clears (approximately 5 half-lives, or 25–35 days for semaglutide and tirzepatide), and the STEP-1 Extension trial showed that participants regained approximately two-thirds of lost weight within 12 months of stopping semaglutide—demonstrating that the metabolic and appetite changes require ongoing pharmacological support. The lean tissue preserved during GLP-1-supported fat loss, however, can be maintained indefinitely if resistance training and adequate protein continue.

Research-grade peptides are synthesized through solid-phase peptide synthesis (SPPS) with exact amino acid sequencing verified by mass spectrometry and HPLC purity testing—guaranteeing that every molecule matches the published structure used in clinical trials. The peptides are typically supplied as lyophilized powder requiring reconstitution with bacteriostatic water and administered via subcutaneous injection at precise microgram or milligram doses. In contrast, most over-the-counter ‘peptide supplements’ contain collagen hydrolysates, amino acid blends, or secretagogue precursors (like arginine and ornithine) that are orally bioavailable but do not contain the actual receptor-active peptides studied in recomposition research. Oral administration of intact peptides like ipamorelin or semaglutide would result in enzymatic degradation in the stomach and intestine before reaching systemic circulation—actual GH secretagogues and GLP-1 agonists require injection to bypass first-pass metabolism and reach target receptors at therapeutic concentrations.

Yes—metabolic enhancers like 5-Amino-1MQ and SS-31 increase energy expenditure through mitochondrial efficiency improvements rather than central nervous system stimulation, avoiding the heart rate elevation, jitteriness, and sleep disruption typical of stimulant-based thermogenics. 5-Amino-1MQ inhibits NNMT to increase NAD+ availability, which activates sirtuins that enhance mitochondrial biogenesis and substrate oxidation—producing a 7% increase in energy expenditure in preclinical models without affecting heart rate or blood pressure. SS-31 stabilizes the inner mitochondrial membrane to reduce proton leak and improve ATP synthesis efficiency, which preserves metabolic rate during caloric restriction when it would normally decline. Neither compound acts on adrenergic receptors or dopamine pathways, so they lack the sympathomimetic effects that limit tolerance and cause rebound fatigue when stimulant thermogenics are discontinued.

Researchers use DEXA (dual-energy X-ray absorptiometry) scans to measure fat mass and lean mass independently, allowing direct quantification of tissue changes that scale weight alone cannot capture—true body recomposition shows fat mass decreasing while lean mass remains stable or increases, even if total body weight changes minimally. Bioelectrical impedance analysis (BIA) provides a lower-cost alternative but with less precision, particularly in detecting small changes in visceral fat or regional muscle mass. Blood biomarkers including serum IGF-1, HOMA-IR (insulin resistance), and nitrogen balance studies further confirm whether observed lean mass preservation reflects actual muscle protein synthesis or simply water and glycogen retention. The gold standard protocols combine DEXA imaging at baseline, week 8, and endpoint with weekly body weight tracking and circumference measurements—allowing researchers to distinguish true recomposition (favorable fat-to-lean ratio) from simple caloric deficit weight loss.